Abstract: The present invention is an improved superfood supplement for dogs.

Abstract: Certain embodiments are directed to an immunogenic composition comprising an immunogenic glycoconjugate comprising a glycan having the chemical formula of galactopyranose (Galp)-?(1,2)-R, Galp-?(1,3)-R, Galp-?(1,4)-R, or Galp-?(1,6)-R, wherein in R is any monosaccharide, oligosaccharide, or polysaccharide, coupled to a carrier peptide or protein. Certain aspects described herein are directed to compounds and therapies for treating Leishmania infections.

Abstract: An object of the present invention is to provide an agent for preventing or treating a fat-associated disease and/or inflammation. The present invention provides an agent for preventing or treating a fat-associated disease and/or inflammation, the agent comprising a Faecalibacterium bacterium or a processed product thereof.

Abstract: Provided are VHH or nanobodies that specifically bind to cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif), and uses thereof for diagnosis and treatment of Pseudomonas infection.

Abstract: The disclosure herein discloses L. plantarum CCFM1019, fermented foods thereof, and application thereof in preparation of a medicine for promoting excretion of plasticizers and metabolites thereof from the body. The L. plantarum CCFM1019 not only is significantly better than the intestinal resident bacteria E. coli and E. faecalis in terms of the effect of promoting the excretion of DEHP and MEHP, but also is better than the commercial strain L. rhamnosus LGG. Therefore, the L. plantarum CCFM1019 of the disclosure can be used as an effective means to prevent and alleviate body damage caused by DEHP and MEHP, and has no toxic side effects of drugs. L. plantarum CCFM1019 can be used to prepare pharmaceutical compositions and fermented foods for alleviating and preventing the toxicity of DEHP and metabolites thereof, and has a very broad application prospect.

Abstract: The present invention relates to an immunoassay for the detection of Borrelia specific IgG, IgM and IgG/IgM antibodies in biological samples suspected of Lyme infection. The immunoassay can be performed via a standard immunoassay format or on an automated platform. In various embodiments, the immunoassay uses one or more Borrelia specific chimeric peptides VlsE-FlaB (designated pFlaB-mV), VlsE-ErpP (designated pErp59-mV), VlsE-P35 (designated pP35-mV) alone or in combination with one or more outer surface protein C (Osp C) types B or I, p58 and DbpA. Other aspects of the invention provide antigen/substrate combinations and compositions comprising combinations of the disclosed peptides and/or proteins for use in the immunoassays described herein.

Abstract: The invention uses ELISA or similar assays for analysing a meningococcal vaccine. The assay uses antibodies which bind to meningococcal proteins within the vaccine, and in particular monoclonal antibodies which are bactericidal for meningococcus and/or which recognise conformational epitopes within the meningococcal proteins. By performing the assay on a series of dilutions of a test vaccine, and by comparing the results with those obtained using a reference vaccine of known potency, it is possible to determine the relative potency of the test vaccine. This value can be used as a parameter for determining whether a manufactured batch of a vaccine is suitable for release to the public, or whether it has experienced a production failure and so should not be used.

Abstract: This disclosure provides a bispecific ligand directed toxin (BLT) that includes a diphtheria toxin (DT) molecule that has been mutated to create a DT molecule that induces less of an immune response than native diphtheria toxin. The deimmunized DT molecule is fused with targeting ligands to create a fusion protein that can selectively deliver the deimmunized DT to target cells to kill the target cells.

Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.

Abstract: Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may also express, surface display, secrete and/or release a tumor-penetrating peptide. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.

Abstract: Microorganisms with increased photosynthetic capacity are described. Increased photosynthetic capacity is achieved by down-regulating activity of the RpaB pathway. The microorganisms include Cyanobacteria, including genetically-modified Cyanobacteria.

Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

Abstract: The present disclosure relates to nanoparticle compositions for use as vaccines against Salmonella.

Abstract: Novel nutritional compositions and methods for their manufacture, administration and use are disclosed. The nutritional compositions of the present invention are useful for the feeding of immature mammals, particularly those used for food, and/or performance animals, such as horses, and for companion animals, such as dogs and cats. The nutritional compositions and supplements of the present invention are effective in supporting the growth and health of the immature mammal, in supporting and stimulating its immune system, and in mitigating undesirable infections and other. Additionally, particular fractions of the unique peptides produced by the disclosed methods can be separated and utilized as therapeutic agents.

Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

Abstract: Provided is a novel preventive or therapeutic agent for celiac disease. A preventive or therapeutic agent for celiac disease, comprising at least one bacterium belonging to the genus Bifidobacterium selected from the group consisting of Bifidobacterium breve and Bifidobacterium bifidum and/or a processed bacterial cell thereof as an active ingredient.

Abstract: A composition of matter for dental plaque removal comprising at least one of a strain of the bacteria Bacillus licheniformis and the extracellular enzymes produced by B. licheniformis, and at least one of a natural and synthetic polymer, are disclosed. A method of manufacturing an animal chew or food item coated with the disclosed composition of matter, and animal chews or food items produced therefrom, are also disclosed.

Abstract: The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using the mutant forms of lysenin.

Abstract: The disclosure is directed to antibodies that bind to Staphylococcus aureus bi-component leukotoxins and/or gamma-hemolysins. Other aspects of the disclosure are directed to pharmaceutical compositions and diagnostic kits containing the leukotoxin and hemolysin antibodies, and therapeutic and diagnostic methods utilizing the leukotoxin and hemolysin antibodies.

Abstract: The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.